866 Malcolm Road, Suite 100
4 articles with ALX Oncology
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
Updated Clinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting in Washington, D.C.
The new name and logo will differentiate ALX Oncology (ALX) from other companies in the field as the Company advances its clinical programs.
Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma
Alexo Therapeutics presented data from the first-in-human Phase 1 study of its lead candidate, ALX148, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma
Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.